🚨#CDH1 alert! Our latest study supports the safety of endoscopic surveillance in asymptomatic CDH1 PV carriers, confirming that recent scientific advances can be successfully applied in a real-world clinical setting 👨🏼‍⚕️. jmg.bmj.com/content/earl...

The INSERM-Sorbonne #PrediLynch dream team! #HorizonEU @glimmerfhu.bsky.social

In our study of 268 #colorectalcancer patients < age 41, prevalence of pathogenic germline variants varied dramatically by phenotype. Unless you have unlimited resources, testing decisions should be phenotype-driven! rdcu.be/edTa5 or www.nature.com/articles/s41... #LynchSyndrome #ejhg